Drug Profile
ACTR 087/SEA BCMA - Cogent Biosciences/Seattle Genetics
Alternative Names: ACTR 087/SEA BCMA; ACTR-BCMA; ACTR087 + SEA-BCMA; ACTR087 + SEA-BCMA combination therapy; SEA BCMA/ACTR 087Latest Information Update: 04 Jul 2021
Price :
$50
*
At a glance
- Originator Unum Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 12 Jan 2021 Cogent Biosciences terminates licensing agreement with National University of Singapore and St. Jude Children’s Research Hospital for development of ACTR constructs
- 05 Oct 2020 Unum Therapeutics is now called Cogent Biosciences
- 12 Feb 2020 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT03266692)